Healthcare is a booming industry, and amongst the leading companies in this space, Guardant Health has emerged as a game-changer. Specializing in precision oncology solutions, the company’s services are highly sought after by patients and medical professionals alike. With such significant offerings, it’s no surprise that institutional investors are keen to get in on the action. Recently, Exchange Traded Concepts LLC indicated just how bullish it is on Guardant Health by raising its position by 61.1% during Q1.
In numbers, this represents an increase of over 18K shares, bringing their holdings to almost 48K – an impressive feat indeed. In terms of equity value, these shares were worth $1.11million at the end of the reporting period. It was revealed that these purchases were funded through the firm’s internal investment accounts and were not subject to any third-party financing.
Guardant Health is no slouch when it comes to its offerings either. The company provides vital blood tests, data sets and analytics – all necessary components for precision oncology treatments. Some of its other services include Guardant360 LDT,Guardant360 Response TestandGuardantINFINITY Testamongst others.
However difficult and complex cancer may be to understand or treat – Guardant Health’s advanced stage tests have shown tremendous growth over recent years which has contributed to its solid market cap of $3.65bn.The company’s business strategy appears robust- evidenced by sound investments from renowned institutions who share their vision for excellence.
As at Friday close-of-day,the stock price quoted stood at $35.53 per share – a fantastic indicator of positive value generation considering Guardant Health’s broad range of services that can potentially be used worldwide.
While valuation could go up or down depending on various factors at play within global markets and healthcare sector operations in general , based on current trends there remains much promise for those looking into investing within this space.
All in all, institutions such as Exchange Traded Concepts LLC who have sat up and taken notice of Guardant Health’s potential to positively impact precision oncology treatments, are setting themselves up for long-term investment success. If the healthcare industry remains on its current growth trajectory, it stands to reason that Guardant Health will continue carving out a solid place within it for many years to come.
[bs_slider_forecast ticker=”GH”]
Guardant Health: A Precision Oncology Company Making Strides in Advanced Cancer Diagnostics
Guardant Health, a precision oncology company based in California, specializes in developing blood tests, analytics and data sets in order to provide advanced diagnostic support for cancer patients. The company’s portfolio includes products such as Guardant360 Response Test and GuardantINFINITY Test, which have proved to be popular among both clinical and biopharmaceutical customers. In May 2017, the company reported Q1 earnings that fell short of analysts’ expectations, with EPS coming in at $1.30 compared to the consensus estimate of $1.26. More positively, however, the company had revenue of $128.71 million for the quarter – above analysts’ estimates of $117.65 million. At the same time as announcing its earnings results, Guardant Health reported Insider Kumud Kalia’s acquisition of 2981 shares at $32.71 each. Several large investors have also recently bought and/or sold shares of the company, including Price T Rowe Associates Inc., Avalon Investment & Advisory and Brandywine Managers LLC. The overall outlook for the stock is positive; despite sporadic fluctuations in price over recent months (with Credit Suisse Group decreasing their price target from $60 down to $55), there are still thirteen buy ratings from leading equity research analysts, according to Bloomberg.com.